Business Description
Firebrick Pharma Ltd
ISIN : AU0000197352
Compare
Compare
Traded in other countries / regions
FRE.Australia IPO Date
2022-01-28Description
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.88 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 12.28 | |||||
| Beneish M-Score | 5.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Book Growth Rate | -45.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.79 | |||||
| 9-Day RSI | 41.83 | |||||
| 14-Day RSI | 45.52 | |||||
| 6-1 Month Momentum % | 12.75 | |||||
| 12-1 Month Momentum % | 15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.19 | |||||
| Quick Ratio | 6.36 | |||||
| Cash Ratio | 2.84 | |||||
| Days Inventory | 2579.66 | |||||
| Days Sales Outstanding | 2007.5 | |||||
| Days Payable | 1598.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5 | |||||
| Shareholder Yield % | -7.43 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -164.29 | |||||
| Operating Margin % | -28057.14 | |||||
| Net Margin % | -8392.86 | |||||
| FCF Margin % | -16750 | |||||
| ROE % | -57.04 | |||||
| ROA % | -48.07 | |||||
| ROIC % | -499.11 | |||||
| ROC (Joel Greenblatt) % | -1194.92 | |||||
| ROCE % | -57.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.09 | |||||
| Price-to-Tangible-Book | 5.6 | |||||
| EV-to-EBIT | -8.62 | |||||
| EV-to-EBITDA | -8.68 | |||||
| EV-to-Revenue | 723.79 | |||||
| EV-to-FCF | -4.32 | |||||
| Price-to-Net-Current-Asset-Value | 5.6 | |||||
| Earnings Yield (Greenblatt) % | -11.6 | |||||
| FCF Yield % | -21.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Firebrick Pharma Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.014 | ||
| EPS (TTM) (A$) | -0.007 | ||
| Beta | 0 | ||
| Volatility % | 122.89 | ||
| 14-Day RSI | 45.52 | ||
| 14-Day ATR (A$) | 0.002309 | ||
| 20-Day SMA (A$) | 0.05975 | ||
| 12-1 Month Momentum % | 15 | ||
| 52-Week Range (A$) | 0.036 - 0.11 | ||
| Shares Outstanding (Mil) | 195.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Firebrick Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Firebrick Pharma Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Firebrick Pharma Ltd Frequently Asked Questions
What is Firebrick Pharma Ltd(ASX:FRE)'s stock price today?
The current price of ASX:FRE is A$0.06. The 52 week high of ASX:FRE is A$0.11 and 52 week low is A$0.04.
When is next earnings date of Firebrick Pharma Ltd(ASX:FRE)?
The next earnings date of Firebrick Pharma Ltd(ASX:FRE) is .
Does Firebrick Pharma Ltd(ASX:FRE) pay dividends? If so, how much?
Firebrick Pharma Ltd(ASX:FRE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers